ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
ASCO 2023 - Checkpoint Inhibitors in Small Cell Lung Cancer
PITTSBURGH, Pa. — Ocean Genomics presented our poster for their AI-driven combined transcriptomic and genomic analysis titled “Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitor Blockade Using ipilimumab/nivolumab in Patients with Extensive Stage Small Cell Lung Cancer” at the American Society of Clinical Oncologists (ASCO) Annual Meeting 2023, on June 2 – June 6, 2023 at the McCormick Place Convention Center in Chicago, Illinois, and has been published in the 2023 ASCO Annual Meeting Proceedings.
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Abstract Title: Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.
Abstract Presentation Number: 8597
Poster Board Number: 224
We had the pleasure of working with two outstanding partners at Yale University School of Medicine/Yale Cancer Center, Anne Chiang, MD, PhD (Associate Cancer Center Director for Clinical Initiatives), and Kurt Schalper, MD, PhD (Director, Translational Immuno-oncology Laboratory), in analysis of their novel single-arm, phase-2 clinical trial (NCT03670056).
The analysis combined whole exome DNA, and RNA-sequencing and was conducted using Ocean Genomics’ Intelligent Transcriptome Platform including our TxomeAI® data analysis pipeline, by members of our computational biology team.
